ISD Immunotech is developing a first-in-class peptide therapeutic to treat severe forms of systemic lupus erythematosus (SLE or Lupus) and other serious autoimmune diseases. In these cases, the immune system dysfunctions and instead of ridding the body of foreign pathogens turns on the body itself attacking vital organs and leading to serious complications which can lead to death. Today there is no approved safe therapy for severe SLE. ISD’s lead program sequesters STING pathway overactivation which has been shown to be linked to Lupus disease severity as well as to other autoimmune diseases. STING is a central target that controls multiple downstream biologic events which activate immune cells and contribute to the disease pathology. ISD has shown that such multifactorial control is required for efficacy in severe patients. The company is at the preclinical stage and has shown strong efficacy in multiple models of SLE included complete protection from Lupus associated kidney pathology. The company is run by a small team of highly experienced pharma and biotech executives and is supported by a world class scientific advisory board. In November 2020 ISD-Immunotech entered into a strategy research collaboration with USA Biotech Giant Biogen to fund the further development of lead candidate ISD-017 for severe Lupus patients.
Established in 2008.